Insulin resistance is inversely related to prostate cancer: A prospective study in Northern Sweden

被引:72
作者
Stocks, Tanja [1 ]
Lukanova, Annekatrin
Rinaldi, Sabina
Biessy, Carine
Dossus, Laure
Lindahl, Bernt
Hallmans, Goran
Kaaks, Rudolf
Stattin, Par
机构
[1] Umea Univ Hosp, Dept Surg & Perioperat Sci Urol & Androl, S-90185 Umea, Sweden
[2] German Canc Res Ctr, Div Canc Epidemiol, D-6900 Heidelberg, Germany
[3] Int Agcy Res Canc, Nutr & Hormones Grp, F-69372 Lyon, France
[4] Umea Univ Hosp, Dept Publ Hlth & Clin Med Behav Med, S-90185 Umea, Sweden
[5] Umea Univ Hosp, Dept Publ Hlth & Clin Med Nutr Res, S-90185 Umea, Sweden
关键词
prostatic neoplasms; insulin resistance; blood glucose; C-peptide; leptin;
D O I
10.1002/ijc.22587
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Factors related to insulin resistance have been implicated in prostate cancer development, however, few analytical studies support such an association. We performed a case control study on 392 prostate cancer cases and 392 matched controls nested in a prospective cohort in Northern Sweden. Plasma concentrations of C-peptide, leptin, glycated haemoglobin (HbA1c) and fasting and post-load glucose were analysed and homeostatic model assessment of insulin resistance (HOMA-IR) was calculated. Conditional logistic regression analyses were used to calculate odds ratios (OR) of prostate cancer. High levels of C-peptide, HOMA-IR, leptin and HbA1c were associated with significant decreases in risk of prostate cancer, with ORs for top vs. bottom quartile for C-peptide of 0.59 (95% Confidence Interval [CI], 0.40-0.89; p(trend) = 0.008), HOMA-IR 0.60 (95% CI, 0.38-0.94; p(trend) = 0.03), leptin 0.55 (95% CI, 0.36-0.84; p(trend) = 0.006) and HbA1c 0.56 (95% CI, 0.35-0.91; p(trend) = 0.02). All studied factors were strongly inversely related to risk among men less than 59 years of age at blood sampling, but not among older men, with a significant heterogeneity between the groups for leptin (p(heterogeneity) = 0.006) and fasting glucose (p(heterogeneity) = 0.03). C-peptide and HOMA-IR were strongly inversely related to non-aggressive cancer but were non-significantly positively related to risk of aggressive disease (p(heterogeneity) = 0.007 and 0.01, respectively). Our data suggest that androgens, which are inversely associated with insulin resistance, are important in the early prostate cancer development, whereas insulin resistance related factors may be important for tumour progression. (c) 2007 Wiley-Liss, Inc.
引用
收藏
页码:2678 / 2686
页数:9
相关论文
共 58 条
[51]   Leptin is associated with increased prostate cancer risk:: A nested case-referent study [J].
Stattin, P ;
Söderberg, S ;
Hallmans, G ;
Bylund, A ;
Kaaks, R ;
Stenman, UH ;
Bergh, A ;
Olsson, T .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (03) :1341-1345
[52]  
STOBIN LH, 2002, UICC TNM CLASSIFICAT
[53]   Relationship of serum leptin levels with body composition and sex steroid and insulin levels in men and women [J].
Thomas, T ;
Burguera, B ;
Melton, LJ ;
Atkinson, EJ ;
O'Fallon, WM ;
Riggs, BL ;
Khosla, S .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2000, 49 (10) :1278-1284
[54]   The influence of finasteride on the development of prostate cancer [J].
Thompson, IM ;
Goodman, PJ ;
Tangen, CM ;
Lucia, MS ;
Miller, GJ ;
Ford, LG ;
Lieber, MM ;
Cespedes, RD ;
Atkins, JN ;
Lippman, SM ;
Carlin, SM ;
Ryan, A ;
Szczepanek, CM ;
Crowley, JJ ;
Coltman, CA .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (03) :215-224
[55]   IGF-I in a normal population: relation to psychosocial factors [J].
Unden, AL ;
Elofsson, S ;
Knox, S ;
Lewitt, MS ;
Brismar, K .
CLINICAL ENDOCRINOLOGY, 2002, 57 (06) :793-803
[56]   The National Prostate Cancer Register in Sweden 1998-2002:: Trends in incidence, treatment and survival [J].
Varenhorst, E ;
Garmo, H ;
Holmberg, L ;
Adolfsson, J ;
Damber, JE ;
Hellström, M ;
Hugosson, J ;
Lundgren, R ;
Stattin, P ;
Törnblom, M ;
Johansson, JE .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2005, 39 (02) :117-123
[57]   Use and abuse of HOMA modeling [J].
Wallace, TM ;
Levy, JC ;
Matthews, DR .
DIABETES CARE, 2004, 27 (06) :1487-1495
[58]  
World Health Organization, 2000, OB PREV MAN GLOB E 1